Cognito Therapeutics vs Genentech

Side-by-side comparison of AI visibility scores, market position, and capabilities

Genentech leads in AI visibility (85 vs 41)
Cognito Therapeutics logo

Cognito Therapeutics

EmergingMedTech

Neurostimulation

Raised $105M oversubscribed Series C (Mar 2026) led by Morningside Ventures. HOPE pivotal trial fully enrolled. Non-pharmacological Alzheimer's device targeting FDA clearance.

AI VisibilityBeta
Overall Score
C41
Category Rank
#1 of 1
AI Consensus
39%
Trend
up
Per Platform
ChatGPT
52
Perplexity
32
Gemini
36

About

Cognito Therapeutics is developing a non-pharmacological treatment for Alzheimer's disease using coordinated gamma-frequency light and sound stimulation — a technology called sensory entrainment that modulates neural oscillations implicated in the disease. The company raised an oversubscribed $105 million Series C in March 2026 led by Morningside Ventures, with its pivotal HOPE clinical trial fully enrolled and topline data expected in late 2026.

Full profile
Genentech logo

Genentech

LeaderLife Sciences & BioTech

Biopharmaceuticals

Roche subsidiary and founding biotech; invented the biologics industry with recombinant DNA. Blockbuster oncology franchise includes Herceptin, Avastin, Rituxan, and Tecentriq.

AI VisibilityBeta
Overall Score
A85
Category Rank
#1 of 2
AI Consensus
57%
Trend
up
Per Platform
ChatGPT
77
Perplexity
95
Gemini
83

About

Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching the modern biotechnology industry. Acquired by Roche in 2009 for $46.8 billion, Genentech continues to operate with significant R&D autonomy as the US hub for Roche's pharmaceutical innovation.\n\nThe company is best known for pioneering cancer biologics, developing Herceptin (trastuzumab) for HER2-positive breast cancer, Avastin (bevacizumab) for multiple cancers, Rituxan (rituximab) for lymphoma, and Tecentriq (atezolizumab) for PD-L1 immunotherapy. Its discovery engine spans oncology, neuroscience, ophthalmology, and immunology with a robust early-stage pipeline leveraging AI-assisted target identification.\n\nGenentech generates tens of billions in annual revenue through Roche's Pharmaceuticals Division and remains one of the most productive biotech research sites in the world, consistently ranked among top employers in life sciences. The South San Francisco campus employs over 13,000 scientists, clinicians, and engineers, anchoring the Bay Area as a global biotech hub.

Full profile

AI Visibility Head-to-Head

41
Overall Score
85
#1
Category Rank
#1
39
AI Consensus
57
up
Trend
up
52
ChatGPT
77
32
Perplexity
95
36
Gemini
83
33
Claude
87
52
Grok
79

Key Details

Category
Neurostimulation
Biopharmaceuticals
Tier
Emerging
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Cognito Therapeutics
Neurostimulation
Only Genentech
Biopharmaceuticals
Genentech is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.